Incyte surged to $102.39 per share this morning, but it remains 7.89% above its mean target price of $94.9. There may still be room for more downwards movement — even after today's 1.1% drop. Analysts are giving the Large-Cap Biotechnology stock on average rating of buy, with target prices ranging from $70.0 to $129.0 per share.
The stock has an average amount of shares sold short at 6.8%, and a short ratio of 4.39. The company's insiders own 1.93% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 104.8% of Incyte's shares being owned by this investor type.
Institutions Invested in Incyte
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-09-30 | Baker Bros. Advisors, LP | 16% | 30,743,663 | $3,147,997,269 |
| 2025-09-30 | Vanguard Group Inc | 10% | 19,951,623 | $2,042,946,370 |
| 2025-09-30 | Blackrock Inc. | 9% | 17,894,297 | $1,832,286,481 |
| 2025-09-30 | Dodge & Cox Inc. | 7% | 13,932,416 | $1,426,609,689 |
| 2025-09-30 | State Street Corporation | 5% | 9,676,796 | $990,855,493 |
| 2025-09-30 | AQR Capital Management, LLC | 4% | 7,923,511 | $811,327,882 |
| 2025-09-30 | Renaissance Technologies, LLC | 2% | 4,528,132 | $463,658,060 |
| 2025-09-30 | Geode Capital Management, LLC | 2% | 4,486,170 | $459,361,362 |
| 2025-09-30 | LSV Asset Management | 2% | 3,986,097 | $408,156,388 |
| 2025-09-30 | Arrowstreet Capital, Limited Partnership | 2% | 3,103,946 | $317,828,540 |
Besides an analyst consensus of little upside potential, other market factors point to there being positive market sentiment on Incyte.
